| KORLYM CORCEPT THERAPEUTICS INC.
1827233 14 Mar 2017 | on 13 Feb 2019 | Class 005 Class 005 Pharmaceutical Products Pharmaceutical preparations for the treatment of psychiatric disorders, namely, psychotic depression, mood disorders, anxiety disorders, cognitive disorders, early dementia (including Alzheimer's disease), cocaine-induced psychosis, psychosis associated with Interferon-alpha therapy, catatonia, postpartum psychosis, depression in patients taking Interleukin-2 (IL-2), treating cognitive side effects of electroconvulsive therapy (ECT), stress disorders, delirium; pharmaceutical preparations for the treatment of endocrine disorders due to hypercortisolemia, namely, endogenous Cushing's Syndrome; pharmaceutical preparations for the treatment of neurological disorders, namely, the prevention of neurological damage in premature infants, migraines, amyotrophic lateral sclerosis (ALS), inhibition of cognitive deterioration in patients with Down's Syndrome | | | KORLYM CORCEPT THERAPEUTICS INC. A DELAWARE CORPORATION
1764283 21 Jan 2016 | on 09 Jan 2020 | Class 005 Class 005 Pharmaceutical Products Pharmaceutical preparations for the treatment of oncologic, endocrine, metabolic, cardiovascular, ophthalmic, and gastroenterologic diseases and disorders. | | | KORLYM CORCEPT THERAPEUTICS INC.
1512137 21 Jan 2011 | on 12 Apr 2017 | Class 005 Class 005 Pharmaceutical Products Pharmaceutical preparations for the treatment of psychiatric disorders, namely, psychotic depression, mood disorders, anxiety disorders, cognitive disorders, early dementia (including Alzheimer's disease), cocaine-induced psychosis, psychosis associated with Interferon-alpha therapy, catatonia, postpartum psychosis, depression in patients taking Interleukin-2 (IL-2), treating cognitive side effects of electroconvulsive therapy (ECT), stress disorders, delirium; pharmaceutical preparations for the treatment of endocrine disorders due to hypercortisolemia, namely, endogenous Cushing's Syndrome; pharmaceutical preparations for the treatment of neurological disorders, namely, the prevention of neurological damage in premature infants, migraines, amyotrophic lateral sclerosis (ALS), inhibition of cognitive deterioration in patients with Down's Syndrome; pharmaceutical preparations for the treatment of metabolic disorders, namely, gastroesophageal reflux disease (GERD), weight gain due to antipsychotic medication. | | 
